Portal de Periódicos da CAPES

Recurrent Pregnancy Loss, Plasminogen Activator Inhibitor‐1 (‐675) 4G/5G Polymorphism and Antiphospholipid Antibodies in Czech Women

2013; Wiley; Volume: 70; Issue: 1 Linguagem: Inglês

10.1111/aji.12099

1600-0897

Ivan Šubrt, Zděnka Ulčová-Gallová, Monika Černá, Markéta Hejnalová, Jitka Slovanova, K Bibková, Z Mičanová,

Protease and Inhibitor Mechanisms

Problem This study compares the frequencies of plasminogen activator inhibitor‐1 (‐675) 4G/5G polymorphism and its relationship with eight antiphospholipid antibodies ( aPL s) in serum of 157 patients with repeated pregnancy loss (RPL). Method of study PAI‐1 (‐675) 4G/5G polymorphism was determined using standard PCR ‐ RFLP method. Enzyme‐linked immunosorbent assay was used for the detection of aPL s against ph‐serine, ph‐ethanolamine, ph‐inositol, ph‐DL‐glycerol, phosphatidic acid, annexin V, cardiolipin, and beta2‐ GPI . Allelic frequency and distribution of genotypes were calculated. The prevalence of the risk conferring 4G allele and 4G/4G homozygous genotype in patients and controls was compared, and the correlation between aPL s positivity and PAI ‐1 4G/4G genotype was tested by chi‐square test. Results Statistically highly significant correlation between RPL and PAI ‐1 (‐675) 4G/4G genotype was found. No correlation between PAI ‐1 (‐675) 4G/5G polymorphism and the presence of antiphospholipid antibodies in RPL patients was observed. Conclusions PAI ‐1 (‐675) 4G/4G homozygous genotype increases the risk of RPL independently from the aPL s positivity.